Form 4: Boston Scientific CEO Executes Options and Sells Shares Under Pre-Arranged Trading Plan

Boston Scientific's Chairman, President, and CEO, Michael F. Mahoney, exercised stock options and subsequently sold a significant number of shares on June 2, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corp (BSX), reported transactions on June 2, 2025.
• He acquired 56,212 shares by exercising stock options at an exercise price of $17.26 per share.
• He also acquired 49,407 shares by exercising stock options at an exercise price of $24.55 per share.
• Concurrently, he disposed of 74,522 shares at a weighted average sale price of $104.0523 per share (ranging from $103.83 to $104.755).
• Additionally, he disposed of 89,921 shares at a weighted average sale price of $103.3902 per share (ranging from $102.83 to $103.825).
• All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on November 15, 2024.
• Following these transactions, Mr. Mahoney directly owns 1,476,882 shares of Common Stock and indirectly owns 201,478 shares through a trust.
• He retains 148,221 unexercised stock options with an exercise price of $24.55.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there's insider selling, it's part of a pre-planned 10b5-1 program, which is a neutral to positive signal for transparency. The executive realized significant gains from option exercises, indicating a strong stock performance relative to the grant prices. The overall impact on company fundamentals is neutral.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned and transparent approach to insider trading, which is generally viewed favorably.
• The significant difference between the option exercise prices ($17.26 and $24.55) and the sale prices ($104.0523 and $103.3902) indicates substantial realized gains for the executive, reflecting positive stock performance since the option grants.

Negatives

• The sale of a significant number of shares by a top executive, even if pre-planned, could be perceived by some investors as a reduction in direct insider alignment with shareholder interests.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a report on insider transactions.

Industry Context

This Form 4 filing reflects a routine insider transaction for liquidity and diversification purposes, common among executives in mature medical technology companies like Boston Scientific. It does not provide insights into broader industry trends or competitive positioning.

Comparison to Industry Standards

• The transactions are consistent with typical executive compensation and liquidity management practices within the medical device industry.
• Executives often exercise vested stock options and sell shares, particularly when the stock price is favorable, as part of pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.
• No specific comparable companies, projects, or results are mentioned in this filing for direct comparison.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be viewed as a slight reduction in direct insider alignment, though the pre-planned nature mitigates negative interpretations. The significant profit realized by the executive from option exercises could be seen positively as a reward for leadership contributing to stock appreciation.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1, Michael F. Mahoney, Beneficial Ownership